Stockreport

uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at the ESGCT 25th Anniversary Congress in Berlin

uniQure N.V. - Ordinary Shares  (QURE) 
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: uniqure.com/investors-newsroom/overview.php
PDF One-time Administration of AMT-130 Demonstrates Survival Benefit and Functional Improvement of Huntington’s Disease Symptoms in Preclinical Study IND-enabling Toxicolog [Read more]